The GLP-1 Effect: How Weight-Loss Drugs Are Rewriting F&B Product Development
TL;DR: 14% of consumers actively improving their diet have started a GLP-1 appetite suppressant, according to Mintel BFY Eating Trends 2025. Combined with 53% focusing on protein, 51% watching portions, and 40% prioritizing fiber, the data points to a fundamental shift in what consumers need from food products. F&B manufacturers face a new design brief: protein-dense, fiber-rich, portion-controlled products that deliver maximum nutrition in smaller servings. The manufacturers who capture this market will be those whose product development infrastructure enables simultaneous multi-SKU reformulation at speed.